Synergistic effects of imatinib (STI 571) in combination with chemotherapeutic drugs in head and neck cancer

Anti-Cancer Drugs

Volumn 16, Issue 7, 2005, Pages 719-726

  Bruce, Iain A ^a,b   Sleving, Nicholas J ^a   Homer, Jarrod J ^a,b   McGown, Alan T ^c   Ward, Timothy H ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^c UNIVERSITY OF SALFORD   (United Kingdom)

Author keywords

Adenoid cystic carcinoma; Antagonism; Cisplatin; Gemcitabine; Head and neck cancer; Head and neck squamous cell carcinoma; Synergy; Tyrosine kinase inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DEOXYCYTIDINE KINASE; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; IMATINIB; MELPHALAN; PACLITAXEL; STEM CELL FACTOR RECEPTOR; VINBLASTINE;

ADENOID CYSTIC CARCINOMA; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CHEMOSENSITIVITY; COMET ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA CROSS LINKING; DRUG ACTIVATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; MONOTHERAPY; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, ADENOID CYSTIC; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; COMET ASSAY; DRUG ANTAGONISM; DRUG SYNERGISM; HEAD AND NECK NEOPLASMS; HUMANS; INHIBITORY CONCENTRATION 50; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 23344444802     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000168392.04676.bb     Document Type: Article

References (38)

1. Buchdunger E, Zimmerman J, Mett H, Meyer T, Muller M, Druker B, et al. Inhibition of the abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996; 56:100-104.
2. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the ABL tyrosine kinase on the growth of bcr-abl positive cells. Nat Med 1996; 2:561-566.
3. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000; 96:925-932.
4. Jeng YM, Lin CY, Hsu HC. Expression of the c-kit protein is associated with certain subtypes of salivary gland carcinoma. Cancer Lett 2000; 154:107-111.
5. Holst VA, Marshall CE, Moskaluk CA, Frierson HF. Kit protein expression and analysis of c-kit gene mutation in adenoid cystic carcinoma. Mod Pathol 1999; 12:956-960.
6. Azzopardi JG, Smith OD. Salivary gland tumours and their mucins. J Pathol Bacteriol 1959; 77:131-140.
7. Jones AS, Hamilton JW, Rowley H, Husband D, Helliwell TR. Adenoid cystic carcinoma of the head and neck. Clin Otol 1997; 22:434-443.
8. Renehan AG, Gleave EN, Slevin NJ, McGurk M. Clinicopathological and treatment related factors influencing survival in parotid cancer. Br J Cancer 1999; 80:1296-1300.
9. Spiro RH. Distant metastasis in adenoid cystic carcinoma of salivary origin. Am J Surg 1997; 174:495-498.
10. Spiro RH. The controversial adenoid cystic carcinoma. In: McGurk M, Renehan A (editors): Controversies in the Management of Salivary Gland Disease. Oxford: Oxford University Press; 2001, pp. 207-211.
11. Suzuki T, Nakagawa T, Endo H, Mitsudomi T, Masuda A, Yatabe Y, et al. The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 ('Iressa') is not related to the expression of Egfr or HER-2 or to K-ras gene status. Lung Cancer 2003; 42:35-41.
12. Magne N, Fischel JL, Dubreuil A, Formento P, Poupon MF, Laurent-Puig P, et al. Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ('Iressa'). Br J Cancer 2002; 86:1518-1523.
13. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82:1107-1112.
14. Prichard MN, Shipman C. A three-dimensional model to analyse drug-drug interactions. Antiviral Res 1990; 14:181-206.
15. Singhal RL, Yeh YA, Szekeres T, Weber G. Increased deoxycytidine kinase activity in cancer cells and inhibition by difluorodeoxycytidine. Oncol Res 1992; 4:517-522.
16. Arner ESJ, Eriksson S. Mammalian deoxyribonucleoside kinases. Pharmacol Ther 1995; 67:155-186.
17. Ward TH, Butler J, Shahbakhti H, Richards JT. Comet assay studies on the activation of two diaziridinylbenzoquinones in K562 cells. Biochem Pharmacol 1997; 53:1115-1121.
18. Kroep JR, Loves WJ, van der Wilt CL, Alvarez E, Talianidis L, Boven E, et al. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol Cancer Ther 2002; 1:371-376.
19. Eby LS, Johnson DS, Baker HW. Adenoid cystic carcinoma of the head and neck. Cancer 1972; 29:1160-1168.
20. Schramm VL, Srodes DS, Baker HW. Cisplatin therapy for adenoid cystic carcinoma. Arch Otolaryngol 1981; 107:739-741.
21. Tannock IF, Sutherland DJ. Chemotherapy for adenoid cystic carcinoma. Cancer 1980; 46:452-454.
22. Vermorken JB, Verweij J, de Mulder PH, Cognetti F, Clavel M, Rodenhuis S. Epirubicin in patients with advanced of recurrent adenoid cystic carcinoma of the head and neck. Ann Oncol 1993; 33:275-278.
23. Chen H, Isoizhaki K, Kinoshita K, Ohashi A, Matsuzawa Y, Kitmarua Y, et al. Imatinib inhibits various types of activating mutant kit found in gastrointestinal stromal tumors. Int J Cancer 2003; 105:130-135.
24. Bauer S, Corless CL, Heinrich MC, Dirsch, Antoch G, Kanja, et al. Response to imatinib mesylate of a gastrointestinal stromal tumour with very low expression of KIT. Cancer Chemother Pharmacol 2003; 51:261-265.
25. Zhang P, Gao WY, Turner S, Ducatman B. Gleevec (STI 571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro. Mol Cancer 2003; 2:1-9.
26. Corless CL, Heinrich MC, Dimitijevic S, Dirnhofer S, Nikolova Z, Fletcher JA. Correlation of imatinib response with activation of Kit and PDGF receptors in a variety of cancers: results of the CSTIB2225 trial. Proc Am Soc Clin Oncol 2003; abstr 783.
27. Alcedo JC, Fabrega JM, Arosemena JR, Urrutia A. Imatinib mesylate as treatment for adenoid cystic carcinoma of the salivary glands: report of two successfully treated cases. Head Neck 2004; 26:829-831.
28. Santini J, Formento JL, Francoual M, Milano G, Scneider M, Dassonville O, et al. Characterization, quantification and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck 1991 ; 13:132-139.
29. Dassonville O, Formento JL, Francoual M, Ramaioli A, Santini J, Schneider M, et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 1993; 11:1873-1878.
30. Campiglio M, Locatelli A, Olgiati C, Normanno N, Somenzi G, Vigano L, et al. Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level. J Cell Physiol 2004; 198:259-268.
31. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003; 2:471-478.
32. Bujia J, Wustrow TP. Expression of epidermal growth factor receptor in squamous carcinoma cell lines of the larynx and hypopharynx. Allergol Immunopathol 1992; 20:152-156.
33. Gieseg MA, de Bock C, Ferguson LR, Denny WA. Evidence for epidermal growth factor receptor-enhanced chemosensitivity in combinations of cisplatin and the new irreversible tyrosine kinase inhibitor CI-1033. Anticancer Drugs 2001; 12:683-690.
34. Friedmann B, Caplin M, Hartley JA, Hochhauser D. Modulation of DNA repair in vitro after treatment with chemotherapeutic agents by the epidermal growth factor receptor inhibitor gefitinib (ZD1839). Clin Cancer Res 2004; 10:6467-6486.
35. Wozniak K, Czechowska A, Blasiak J. Cisplatin-evoked DNA fragmentation in normal and cancer cells and its modulation by free radical scavengers and the tyrosine kinase inhibitor STI 571. Chem-Biol Interact 2004; 147:309-318.
36. Bradford CR, Zhu S, Ogawa H, Ogawa T, Ubell M, Narayan A, et al. P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. Head Neck 2003; 25:654-661.
37. Bellone G, Ferrero D, Carbone A, De Quadros MR, Gramigni C, Pra A, et al. Inhibition of cell survival and invasive potential of colorectal carcinoma cells by the tyrosine kinase inhibitor STI 571. Cancer Biol Ther 2004; 3:385-392.
38. Slevin NJ, Mais KL, Bruce I, Ward T, Carrington B, Hulse P, et al. Imatinib with cisplatin in recurrent and/or metastatic salivary adenoid cystic carcinoma-response assessed by FDG-PET scanning. J Clin Oncol 2004; 22(14S):5604.